α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Abstract Background Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human patients, responses to checkpoint blockade therapy correlate with tumor mut...

Full description

Bibliographic Details
Main Authors: E. Dodagatta-Marri, D. S. Meyer, M. Q. Reeves, R. Paniagua, M. D. To, M. Binnewies, M. L. Broz, H. Mori, D. Wu, M. Adoumie, R. Del Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus, D. Sheppard, B. C. Hann, A. Mirza, S. A. Quezada, M. D. Rosenblum, M. F. Krummel, A. Balmain, R. J. Akhurst
Format: Article
Language:English
Published: BMJ Publishing Group 2019-03-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Checkpoint blockade
Squamous cell carcinoma
Tumor mutation load
α-TGFβ /α-PD-1 combinatorial immunotherapy
Tregs
pSmad signaling
Online Access:http://link.springer.com/article/10.1186/s40425-018-0493-9

Internet

http://link.springer.com/article/10.1186/s40425-018-0493-9

Similar Items